Led · Series A · Aug 2026

Kynexis is developing KYN-5356, a potential first-in-class oral small-molecule inhibitor of KAT-II intended to reduce brain kynurenic acid (KYNA) and restore signaling involved in cognition. The company’s initial clinical focus is cognitive impairment associated with schizophrenia (CIAS), with plans to expand into other cognitive disorders including Alzheimer’s disease. KYN-5356 is the company’s most advanced program and has demonstrated favorable safety, central nervous system penetration, and dose-dependent reductions in cerebrospinal fluid KYNA in Phase 1. Kynexis has completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 trial of ~150 adults across 13 U.S. sites evaluating a 28-day adjunctive treatment and expects topline results by the end of 2026. The company has a U.S. subsidiary based in Cambridge, Massachusetts, and recently added senior business development leadership to support its clinical and corporate strategy.

Led · Series B · Mar 2022

Epsilogen's core product is MOv18 IgE, the first therapeutic IgE antibody to enter the clinic, which targets folate receptor alpha (FRα) expressed on multiple solid tumours. A completed Phase I trial showed MOv18 IgE to be safe and well tolerated with initial signs of clinical activity reported in Nature Communications. The company has completed large-scale GMP manufacture of MOv18 IgE and will initiate a Phase Ib two-part dose-escalation and expansion trial in FRα-positive platinum-resistant ovarian cancer later this year. Epsilogen is also developing a broader IgE-based pipeline, including IgE bispecifics and IgE/IgG combination molecules (IgEGs). The recent financing will fund delivery of clinical proof of concept for MOv18 IgE and further development across the IgE pipeline. Epsilogen develops novel immunoglobulin E (IgE) antibodies to treat cancer, with a focus on solid tumours. Its lead candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic. Data from a phase I trial showed MOv18 IgE to be safe and well tolerated with early signs of clinical activity. The company plans to establish clinical proof of concept for MOv18 IgE in a phase Ib trial in platinum-resistant ovarian cancer. Epsilogen is also advancing a proprietary IGEG antibody platform that combines elements of IgE and IgG to create molecules with enhanced functionality. The recent financing will fund the phase Ib study and continued development of the IGEG platform. Epsilogen began operations in 2017 as a King’s College London spin-out leveraging Professor Sophia Karagiannis’s IgE expertise.

Participated · Equity · Sep 2021

Tact.ai Technologies, Inc. announced it received $33 million in an equity round of funding on September 20, 2021. The transaction included participation from new investors dRx Capital AG, Eli Lilly and Company, and McKesson Ventures, alongside returning investors M12 and Salesforce Ventures, LLC. The financing was an equity round. With this transaction the company has raised a total of $88,000,000 to date. The article does not provide details on the company's products, business model, revenue, users, or future plans. No additional terms or instruments were disclosed in the article. Tact builds a voice-driven interface that helps salespeople add and retrieve CRM information hands-free, aiming to reduce the friction of interacting with CRM systems. The company integrates with voice platforms and was one of the first services on Alexa for Business. Tact recently announced a "Voice Intelligence" car-based virtual assistant that surfaces meeting, deal and service-ticket context to field sales reps. CEO Chuck Ganapathi, who has more than 20 years building CRM systems, founded Tact in 2012 with the vision of using voice to improve sales productivity. The company has raised capital to support product development and distribution and has now raised over $53 million, according to Crunchbase.

Participated · Series C · Jul 2021

Artios exploits a DDR‑based platform and small‑molecule drug discovery capabilities to build a pipeline of next‑generation cancer therapies. Its pipeline includes ATR inhibitor ART0380, which is in a Phase 1 clinical study, and a potential first‑in‑class DNA polymerase theta (Polθ) inhibitor ART4215 planned for first‑in‑human studies in the second half of 2021. The company collaborates with Cancer Research UK and research groups including The Institute of Cancer Research, the Netherlands Cancer Institute and the Crick Institute. Artios has partner agreements with Merck KGaA (opt‑in on up to eight targets with milestone potential of up to $860M per target) and a collaboration with Novartis that included a $20M up‑front payment and up to $1.3B in milestones plus royalties. Artios is based at the Babraham Research Campus in Cambridge, UK, and has an office in New York City. The company has strengthened its balance sheet through equity financings, including a $153M Series C, bringing total capital raised to more than $320M to date. Artios is a Cambridge-based biotech focused on developing cancer therapeutics. The company was the subject of an $84 million development round reported in the article. That financing attracted participation from large pharmaceutical companies Pfizer and Novartis. The round is described as a development-stage financing intended to advance the company’s oncology drug programs. The deal underscores continued investor interest in cancer drug development. No operating metrics or additional financial terms were disclosed in the article.

Participated · Seed · Jan 2021

Peptone is a London, UK–based molecular computational physics company focused on protein drug discovery. It combines advanced biophysics, atomic-level experimental approaches, high-performance supercomputing, and machine learning to address biopharmaceutical R&D challenges. The company concentrates on intrinsically disordered proteins (IDPs), a class of proteins without fixed structure that play significant roles in health and disease and have been historically difficult to drug. Peptone's proprietary approaches aim to explore IDPs and enable discovery of novel therapeutics against previously undruggable targets. In June 2022 Peptone closed a $40M Series A financing. The round will be used to develop an advanced facility dedicated to solving complex and problematic IDP structures at scale and to pioneer a new class of potential therapeutic targets and drugs. Peptone is a computational physics company that developed one of the world’s first protein engineering operating systems, PeOS. PeOS uses state-of-the-art computational molecular physics orchestrated by AI and reinforcement learning to run massively parallel molecular simulations. The platform sifts through millions of protein feature anomalies to assess the likelihood of failure and suggests routes to resolution, automating the search for non-obvious protein variants with therapeutic potential and manufacturability. The team, led by physicist and founder Dr. Kamil Tamiola and including co-founders Kamil and Matt, comprises physicists, structural biologists, computer engineers and mathematicians who spent years building the foundations of PeOS. Peptone collaborated exclusively with NVIDIA to develop its supercomputing and AI solutions. The company is in talks with pharmaceutical players about partnerships and has raised funding to further develop its technology and reduce early-stage drug development failure risk.